Articles
CLINICAL FOCUS Primary Psychiatry. 2008il5(5):52-58
Over-the-Counter Sleep Aid Medications and Insomnia Surilla Randall, PhD, Timothy A. Roehrs, PhD, and Thomas Roth, PhD
ABSTRACT Insomnia is defined as difficulty initiating or maintaining sleep
and/or nonrestorative sleep which impairs daytime function. Self
treatment with over-the-counter (OTC) sleep aids, herbal and dietary
supplements, and/or alcohol is common. Problems associated with
insomnia self treatment are ineffectiveness, tolerance, dependency,
and potentially harmful side effects. Studies of OTC sleep aids and
other non-prescription sleep aids such as antihistamines, valerian,
melatonin, and L-tryptophan have inconsistent results and lack
objective data on both their efficacy and safety. Lastly, alcohol
should never be used as a sleep aid due to its abuse liability.
INTRODUCTION The Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision,' defines primary insomnia as difficulty initiating or maintaining sleep and/or poor quality (nonrestorative) sleep for at least 1 month, which has some daytime consequences. The duration of insomnia can be tran- sient (days to several weeks) or chronic (>1 month). Insomnia is associated with impairments in social, occupational, and other areas of functioning. Sleep disturbances can have a significant negative impact on daytime function, evident by mental slow- ing, reduced concentration, memory lapses, and decreased motivation. Insomnia can be associated with medical condi- tions, medication use, psychiatric disorders, substance abuse, or other primary sleep disorders (eg, sleep apnea, restless leg syn- drome). However, primary insomnia is a disorder independent of these other conditions,
Epidemiologic studies report varying estimates of insomnia prevalence. The estimates are dependent upon whether the
Needs Assessment: QMmm insomnia is reported by 10% to 15% of the popuiation and the morbidity of untreated insomnia is now weli documented. Beyond the quaiity of life and psycbosociai risks, insomnia is associated with increased risk of psychiatric disorders and exacerbation of medical disorders. Medical treatment of chronic insom- nia with Food and Drug Administration-indicated drugs is not common, but insomniacs do use other available substances and physicians prescribe off-label medications. Insomniacs' use of ineffective and in some cases potentially dangerous self treatments is not fully appreciated as a risk of not treating the patient presenting with Insomnia. Insomniacs use various over-the-counter medications and herbal substances for which there is limited data regarding their efficacy and safety. This article provides an over- view of the available information regarding these various self-treatments.
Learning Objectives:
• List the major categories of over-the-counter (OTC) sleep aids. • Describe the current hypotheses of the mechanisms in which the various OTC sleep
aids work. • Explain the concerns regarding the safety and efficacy of insomnia self treatment.
Target Audience: Primary care physicians and psychiatrists.
CME Accreditation Statement This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mourit Sinai School cf Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: J^i Mount Sinai School of Medicine designates this educational activity for a maximum of 3 AMA PRA Category 1 Creditisf. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Policy Statement: It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sporisored educational activities. All faculty participating in the plan- ning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclo- sure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
This activity has been peer-reviewed and approved by Eric Hollander, MD, chair and professor of psychiatry at the Mount Sinai School of Medicine, and Norman Sussman, MD, editor of Primary Psychiatry zni professor of psychiatry at New York Llniversity School of Medicine. Review Dafe: March 27, 2008.
Drs. Hollander and Sussman report no affiliation with or financial interest in any organization that may pose a conflict of interest.
To receive credit for this activity: Read this article and the two CME-des- ignated accompanying articles, reflect on the information presented, and then complete the CME posttest and evaluation found on page 85. To obtain credits, you should score 70% or better. Early submission of this posttest is encouraged: please submit this posttest by May 1,2010 to be eligible for credit. Release date: May 1,2008. Termination date: May 31,2010. The estimated time to complete all three articles and the posttest is 3 hours.
Dr. Randall is postdoctoral fellow in the Sleep Disorders and Research Center at the Henry Ford Hospital in Detroit, Ml. Dr Roehrs is director ot research at the Sleep Disorders and Research Center at the Henry Ford Hospital and professor of psychiatry in the Department of Psychiatry and Behavioral Neuroscience at Wayne State University School of Medicine in Detroit. Dr. Roth is director of the Sleep Disorders and Research Center at the Henry Ford Hospital and professor of psychiatry in the Department ot Psychiatry and Behavioral Neuroscience at Wayne State University School ot Medicine.
Disclosure: The authors report no affiliation with or tinancial interest in any organization that may pose a contlict of interest
Please direct all correspondence to: Surilla Randall, PhD, Heniy Ford Hospital Sleep and Research Center, CFP-3, 2799 West Grand Blvd, Detroit, Ml 48202; Tel: 3 1 3 - 9 1 6 - 5 3 0 1 : Fax: 313-916-2508; E-mail: srandall@hfhs.org.
Primary Psyctiiatry 52 May 2008
Over-the-Counter Sleep-Aid Medication and Insomnia Q
data come from patient care settings; female, elderly, or general populations; or the study's definition of insomnia.^ Taking into consideration the various adult insomniac populations, preva- lence estimates range from approximately 10% to 50%. When including only chronic insomnia the prevalence range decreases from 10% to 15%.̂ -'̂
Insomnia predisposes one to psychiatric disorders, aggravates medical conditions, decreases the quality of life, and increases the risk of drug and alcohol abuse.^ Greater than 50% of those with depression, psychosomatic disorders, anxiety disorders, neuroses, dementia, and schizophrenia have insomnia com- plaints.^ In some cases, treating the underlying mental disease may not improve the insomnia.
Self treatment with over-the-counter (OTC) sleep aids, herbal and dietary supplements, and/or alcohol is common among insomniacs. It is thought that the availability of these products, decreased cost compared to prescription sleep aids, and importantly, perceived safety results in the great usage of OTC sleep aids.'̂ '" A metropolitan Detroit study'" showed that 25.9% of respondents reported using some substance to aid their sleep. Of those who used medications (either prescrip- tion, OTC sleep aids, or both) to improve sleep, 57% reported using OTC sleep aids. In a recent study,'^ approximately 25% of patients with insomnia used OTC sleep aids, and 5% used these drugs several times a week. A study of insomniac women >85 years of age noted that the respondents reported they did not see a physician or nurse practitioner for insomnia until the self treatment (with alcohol, OTC sleep aids, or both) was no longer effective." The problems associated with insomnia self treatment are use at higher than recommended doses, tolerance resulting from loss of efficacy, and the development of depen- dency in at-risk populations. There are even greater concerns with alcohol used as a sleep aid. Ineffective and potentially harmful self treatment is not fully appreciated as a risk of not treating insomnia medically with drugs exhibiting efficacy and safety profiles. This article provides an overview of what is known regarding the efficacy and safety of popular nonpre- scription products used for insomnia.
ANTIHISTAMiNES Antihistamines consist of a broad class of pharmacologic
agents that include the first-generation, central acting histamine (H)i receptor antagonists. The primary action of this drug class is to block the effects of histamine, which reduces congestion, sneezing, coughing, and allergy symptoms. Centrally, these drugs block histamine receptors, histamine being one of the major alerting central neurotransmitters. Due to the sedative action of antihistamines, they are widely used as non-prescrip- tion sleep aids. Evidence appears to suggest that antihistamines may be useful for insomnia for 1-2 nights, but not efficacious in treating chronic insomnia.
Diphenhydramine
In 1982, the Food and Drug Administration authorized the initial marketing of diphenhydramine HCl and diphenhydr- amine citrate as active ingredients in non-prescription sleep aids. Other general medical uses include relief of allergies, motion sickness, and coughing. Table 1 lists the various OTC products and their doses. For sleep, the available dose range of diphenhydramine is 25-50 mg, with 50 mg being the maxi- mum dose to be taken 30-60 minutes before bed.'"*'' While marketed for allergy relief, Benadryl, which contains 12.5 or 25 mg of diphenhydramine depending on the formulation, is commonly used for sleep. Diphenhydramine citrate is often combined with an analgesic; together they are advertised to provide pain relief and induce sleep (Table 1).
Diphenhydramine has a half-life of 5-12 hours and has sig- nificant anticholinergic activity. Consequendy, its use is associ- ated with next-day mild-to-moderate side effects, namely resid- ual morning sedation, dry mouth, grogginess, and malaise.'^'^ Importandy, it has not been determined which aspects of its pharmacologic activity are mediated by H] receptors and which are mediated by cholinergic receptors. Despite the reported side effects of diphenhydramine, virtually all OTC sleep aids contain diphenhydramine as the active ingredient (Table 1).
The use of diphenhydramine is common, but the number of controlled trials that support its efficacy are limited and many lack objective data. Several studies show evidence of sedative properties. One-week administration of diphen- hydramine (50 mg) significantly decreased self-reported sleep latency and improved sleep depth and quality."" Similar results were reported in psychiatric patients with insomnia following nightly administration of 12.5-50 mg of diphenhydramine for 2 weeks. Sleep quality, duration of sleep, and severity of insomnia symptoms significantly improved as measured by self reports." Interestingly, global improvements in sleep were significantly greater in those who had not received previous treatment for insomnia." This finding suggests drug tolerance, cross-drug tolerance, or that the efficacy of diphenhydramine is not as robust as other pharmamocologic treatments. Tolerance to the hypnotic effects of diphenhydramine was evident on both objective and subjective measures of sleepiness following 3-4 days of administration.'^ Thus, only short-term use is recommended since physical tolerance, can develop.'^'^
For several reasons, it is advised that those with chronic medical conditions should not take diphehydramine, and specific precautions should be considered in those with car- diovascular disease, hypertension, or lower respiratory disease. Diphenhydramine produces additive central nervous system effects when taken concomitantly with alcohol, hypnotics, anx- iolytics, narcotic analgesics, and neuroleptic drugs. Similarly, significant interactions may occur if the drug is taken concomi- tantly with anticholinergic agents or tricydic antidepressants.
Primary Psychiatry 53 May 2008
J S. Randall, T.A. Roehrs, T. Roth I _ _ ^ :
TABLE 1
OTC SLEEP-AID MEDICATIONS* AntJhJstamJnes
Active Ingredients
Diphenhydramine HCi
Diphenhydramine HCi (pain reiief with sleep aid)
Diphenhydramine Citrate (pain relief with sleep
aid)
Doxylamine Succinate (pain relief with sleep aid)
Melatonin
Valerian
St. John's Wort
Tryptophan
Brand Name
Nyfol Sleep Aid (Regular Strength)
Sominex Original Formula
Tylenol Simply Sleep
Nytol Sleep Aid (Extra Strength)
Sominex
Maximum Strength Formula
Unisom SleepGels Maximum Strength
Doan's PM Nighttime Back Pain Relief & Sleep Aid
Legatrin PM
Excedrine PM
Advil PM
Bayer PM
Unisom SleepTabs
Goodsense Sleep Aids Tablets
Kirkland Nighttime Sleep Aid
Herbs and Supplements
Melatonex
Nature's Bounty
Natrol
Nature Made
GNC Melatonin
Nature Made
Nature's Resource Valerian
Herbal Plus Valerian Root
Nature's Fingerprint Valerian Root
Nature Made
Sundown
Nature's Resource Time Release
Nature's Fingerprint
Cyence Labs L-Tryptophan 500
Xenadrine Sleep Plus with L- Tryptophan
Cyence Labs L-Tryptophan 1,000
Dose (m
25
25
25
50
50
50
25
50
38
38
38.8
25
25
25
3
l/3/5t
3/5+
3 1/3*
400 400 500 500
150
300 450
500
500
500
1,000 ms
* This table is not exhaustive, but it represents active ingredients found in OTC sleep-aid medications that purport sleep-inducing properties.
t Can be purchased at multiple doses.
OTC=over-the-counter; GNC=General Nutrition Centers.
Randall S, Roehrs TA, Roth T Primary Psychiatry. Vol 15, No 5. 2008.
Doxylamine
In 1978, the FDA approved doxylamine succinate as an active ingredient for O T C sleep aid use. Doxylamine succinate medi- ates its activity through the H] receptor. Doxylamine has minimal effeas on sleep onset due to its relatively long time to maximum plasma concentration. The time for sleep to be achieved is 45-60 minutes after oral administration. The peak plasma concentration is not reached until 90 minutes after administration. Using patient report outcomes, doxylamine (25 mg) for 1 week significandy decreased sleep latency." The authors of this article are unaware of any further published O T C efficacy studies for doxylamine. The elimination half-life is 10.1 hours. Thus, upon waking, plasma levels of doxylamine are present; consequently, residual daytime sedation is a documented side effect. Doxylamine is also potentially dangerous in accidental or intentional overdose. Rhabdomyolysis and secondary acute renal failure are rare but potentially serious complications, making early recognition and treatment essential.^" H , antihistamines are not recommended for the elderly due to potential adverse effects and drug interactions. Doxylamine shares the same mechanism of action as diphenhydramine and the poten- tial for tolerance to doxylamines sedative effects exists.
SUPPLEMENTS AND HERBS In the United States, usage of complementary and alternative
medicines showed a secular upward trend from 33.8% to 42.1% for treatment of any health condition between 1990 and 1997. In comparison, treatment for insomnia rose from 20.4% in 1990 to 26.4% in 1997.^' Supplements and herbs are perceived as "natural" and, therefore, a safe alternative to prescription medications and some OTC products. The FDA does not rigor- ously test or regulate manufacturing of supplements and herbs. Currently, no FDA regulations specific to dietary supplements require a minimum standard for manufacturing of dietary sup- plements. Thus, the manufacturer is responsible for the strength, purity, composition, and safety of their products. According to FDA regulations, supplement manufacturers are forbidden to market their product as a treatment, prevention, or cure, for any medical disorder, including insomnia.
Supplements and herbs have reported side effects and incon- sistent clinical fmdings, so the risk to benefit is questionable. Care should be used when taking these substances because they still cause physiologic changes in the body and can interact with other medications (Table 2).
Valerian
Valerian is a flowering plant that includes >200 species. The species Valeriana officinalis is most often used in the treatment of anxiety and insomnia. Valerian preparation methods vary with several different extraction methods used. The aqueous
Primary Psychiatry 54 May 2008
____J^ J Over-the-Counter Sleep-Aid Medication and Insomnia ;
extraction method produces doses range from 270-900 mg and ethanolic valerian extraction doses range from 300-600 mg.̂ ^ Other valerian species {V edulis and V. wallichii) have active ingredients that are minimally present in V. officinalis. The chemical ingredients in valerian products vary depend- ing on the plant species and the extraction method. Valerian roots are prepared as teas and dried plant material and extracts are compounded into capsules or incorporated into tablets. A possible mechanism in which valerian causes sedation is by inhibition of the breakdown of y-aminobutyric acid (GABA) or GABA-Iike metabolites.^^
The sleep research evaluating the efficacy of valerian as a sleep aid has produced inconsistent results. Variations in study participants, study design, and methodology; valerian prepara- tion; dose; and sleep assessment measures likely account for the mixed results for valerian.
Valerian 400 mg administered on three nonconsecutive nights produced a significant decrease in self-reported sleep latency, which was notable in people >40, men, and those who con- sidered themselves poor or irregular sleepers. Poor or irregular sleepers and those who considered themselves as having long sleep latencies also reported significant improvements in sleep quality.̂ '* Significant decreases in self-reported sleep latencies were also found in healthy subjects without major sleep distur- bances following one valerian dose of either 450 or 900 mg. Only the 900 mg dose reduced wake time after sleep onset using
TABLE 2
SIDE EFFECTS WITH NONPRESCRIPTION SLEEP AIDS
Sleep Aid Side Effects and Precautions
Antihistamines Residual daytime sedation, drowsiness, dry mouth, toler- ance, may interact with other medications
Valerian Headache, dizziness, gastrointestinal disturbances, daytime sleepiness, nervousness, anxiousness, heart palpitations
St. John's wort Increase sensitivity to sunlight, anxiety, dry mouth, diz- ziness, gastrointestinal symptoms, fatigue, may interact with other antidepressants
Kava Skin rash, tiredness, gastrointestinal disturbances, muscle weakness, loss of coordination, vision changes, drinking alcohol can be contraindicated, liver disease with excessive use
Melatonin Headaches, daytime sleepiness, dizziness, nausea, abdomi- nal discomfort, confusion, sleepwalking or nightmares
L-Tryptophan Drowsiness, dizziness, dry mouth, headache, nausea, may interact with other antidepressants, avoid exces- sive exposure to ultraviolet light to reduce the chance ot cataract tormation
Alcohol Dependency, tolerance, negative impact on the sleep quality, disturbs sleep cycle, can cause snoring, can cause apnea episodes in those who do not normally have symptoms.
Randall S, Roehrs TA, Roth T. Primaty Psychiatry. Vol 15, No 5. 2008.
self reports. The self ratings of sleep quality were not significandy different among treatments (0, 450, and 900 mg).
In an uncontrolled case study, insomniacs receiving mental health services took valerian for 14 days to supplement their psychotropic regimen. Doses of valerian started at 470 mg (one pill) on nights 1—3 and the insomniacs could increase their dose to a maximum of 1,410 mg (three pills) after week 1. Dose escalation occurred if lower doses proved to be insuf- ficient. After 1 week of treatment, 11 of the 20 participants reported that valerian "moderately" improved their insomnia at the 940 mg dose (two pills). By week 2, all increased their dose to 1,410 mg, nine rated their insomnia "moderately to extremely" improved, and six rated their insomnia "extremely" improved.^' There was no discussion as to what aspect of their sleep disturbances was improved.
Chronic insomniacs were given valarian 450 mg for 1 week and were required to maintain sleep diaries. Valerian was not shown to be appreciably better than placebo adminstration in a series of randomized n-of-1 trials.̂ *̂ Similarly, valerian (6.4 mg) for 28 days did not relieve insomnia or anxiety to a greater extent than placebo in an Internet-based study. Adverse events occurred with similar frequency between the treatment group and the placebo group except that significantly more reports of diarrhea (18% of 114) occurred in the valerian group com- pared to those receiving placebo (8%).^''
Polysomnography (PSG), the concurrent recording of elec- troencephalograph (EEG), electromyogram, and electrooculo- gram, is the standard method of objectively assessing sleep. It is often combined with computer analyses of EEG frequency and power (ie, spectral analyses). PSGs and spectra analyses of sleep EEG showed no significant differences between a 900 mg valerian dose and placebo administration in healthy volunteers. No adverse events or side effects were reported.^^ Results of objective assessments of sleep latency have varied. Actigraphy, recording movements of arms or legs, is a less labor-intensive and intrusive method of assessing sleep than PSG. Actigraphs, worn by eight mild insomniacs, showed decreases in sleep latencies following valerian 450 mg for 4 nonconsecutive nights. In contrast, 900 mg did not produce a further improve- ment in sleep latencies and the higher dose had significantly greater morning sleepiness associated with it.^' In a PSG study, no significant decrease in sleep latency was demonstrated fol- lowing 8 consecutive days of valerian (405 mg on day 1 and 1,215 mg on days 2—8) in 14 elderly female insomniacs. On other sleep measures, this dosing produced selective effects on non-rapid eye movement (REM) sleep stages. Non-REM is characterized by slower brain activity, divided into sleep stages 1-4, and is not associated with dreaming. Relative to baseline, valerian decreased the percentage of stage 1 sleep on night 1 and further decreased it on night 8. No systematic change occurred in the placebo group. Slow wave sleep (SWS; sum of sleep stages 3 and 4) significantly increased from baseline to
Primary Psychiatry 55 May 2008
S. Randall, T.A. Roehrs, T. Roth L ^
night 8. REM sleep (sleep stage characterized by active brain waves and dreams) was unaltered by valerian.^"
Sixteen insomniacs given valerian 600 mg for 14 days showed significant decreases in SWS latency in comparison to placebo, and a significant increase in the percentage of SWS compared to baseline as measured by PSG. Other sleep parameters were not significantly altered. Only three indepen- dent side effects or adverse effects occurred following valerian administration, which included one episode of gastrointestinal complaints, migraine, and an accident associated with the PSG procedures. Subjective measures of sleep and other sleep parameters were not significantly altered.^' Overall, these double-blind data suggest that although valerian is safe it does not improve the symptoms of disturbed sleep.̂ ^ It would be interesting to pursue the question of the increase in slow-wave sleep, its clinical significance, and the degree to which this is mediated by GABA.
Valerian is frequently combined with other herbal extracts such as hops and lemon balm, each purportedly having their own sedative or tranquilizing effects. A valerian preparation (valerian 400 mg, hops 375 mg, and lemon balm 160 mg) was rated better than control following one night of administra- tion. No side effects were reported with this preparation.^^ In contrast, for 3 nonconsecutive nights a commercial preparation of valerian 120 mg and hops 60 mg produced no significant change in sleep latency or sleep quality on subjectively rated sleep measures in healthy normal volunteers. This valerian prep- aration resulted in significantly greater reports of "more sleepy than usual" responses in comparison to the placebo group.^' Similar results were reported in mild insomniacs administered a valerian (374 mg)-hops (83.8 mg) combination for 28 days. This dosing and duration failed to produce a significant effect in sleep parameters using sleep diaries and PSG.
St. John's Wort
St. John's wort {hypericum perforatum) is the medicinal herb used for a variety of ailments including depression, anxiety, and fatigue. The active components are thought to be hyper- forin and hypericin, although different formulations vary in their level of constituents.'"* Most clinical studies focus on the treatment of depression rather than insomnia. No published double-blind placebo controlled studies were found using St. John's wort to ameliorate primary insomnia.
Kava
Kava (or kava kava) comes from the roots of the Polynesian plant Piper methysticum is indigenous to the South Pacific. Supplements containing kava are marketed to alleviate meno- pausal symptoms, anxiety, and insomnia. Liver damage may be a risk factor associated with kava, and the FDA issued an advisory to consumers of this important potential risk. A meta-
analysis of kava in the treatment of anxiety reported adverse events such as stomach complaints, restlessness, tremor, head- ache and tiredness (Table 2).^'
Stress-induced insomnia was ameliorated after 6 weeks of 120 mg of kava and farther improved by 6 weeks of valerian (600 mg) as measured by sleep questionnaires. There was a 2-week wash-out period between both treatments and, importantly, sleep during the washout did not differ from baseline. Side effects of kava included, diarrhea, gastric disturbances, and dry mouth."'
A frequent symptom associated with anxiety disorder is sleep disturbances. Kava 300 mg for 28 days did not significantly relieve anxiety or insomnia symptoms tising the Insomnia Severity Index and State-Trait Anxiety Inventory, respectively.̂ '' In contrast, significant improvements relative to placebo in sleep quality and the recuperative effects of sleep as well as decreases in anxiety were demonstrated in patients with sleep disturbances associ- ated with anxiety of non-psychotic origin following kava 200 mg (WS*l490) for 4 weeks.̂ ^ Sleep questionnaires such as the Hamilton Rating Scale for Anxiety, self-rating scales of well being, and the Glinical Global Impressions scale showed improvements in sleep and anxiety. No drug-related adverse events or changes in clinical or laboratory parameters were noted.
As is the case in many of these products, there are some non- controlled data suggesting efficacy. However, objective and/or other placebo controlled trials that further suggest efficacy for insomnia are limited. Further, the benefit has to balanced against the risk, and the potential of liver toxicity in the case of kava cannot be dismissed.
NEUROHORMONES AND TRANSMITTER PRECURSORS
Melatonin
The pineal gland produces the neurohormone melatonin (7V- acetyl-5-methoxytryptamine). Synthesis and secretion occurs nocturnally by darkness and is inhibited by environmental light, which suggests that melatonin is involved in modulating circadian rhythm. Melatonin secretion starts at approximately 9:00pm and peaks between 2AM and 4AM.'^ Melatonin supplements are commonly used to combat jet lag and sleep disturbances, to protect cells from free-radical damage, and for enhancement of immune function. The mechanism by which melatonin affects sleep, beyond its circadian signaling capabil- ity (phase shifting), is unknown, but it likely involves stimula- tion of melatonin receptors.^
The half-life of melatonin ranges from 0.54—2 hours; with doses ranging from 0.3-5.0 mg, melatonin is less likely to cause residual daytime drowsiness. Side effects reported in the litera- ture included headache, odd taste in mouth, and poor sleep quality (Table 2).^' Melatonin supplements are relatively safe
Primary Psychiatry 56 May 2008
Over-the-Counter Sleep-Aid Medication and Insomnia ; ;
when used short term over days or weeks. However, the safety of melatonin over months has not been studied.
Riemann and colleagues'"' showed significant decreases in nighttime melatonin concentrations in insomniacs, and others have shown delays in melatonin secretion. However, several double-blind, placebo-controlled studies have failed to show the effectiveness of supplemental melatonin in treat- ing primary insomnia. Melatonin in doses that range from 0.3-5 mg showed no significant differences over placebo in sleep measures such as sleep efficiency; total sleep time; latency to sleep; number of nocturnal awakenings; average length of the non-REM-REM cycle; percent of stage 1, 2, delta sleep, and REM sleep; total minutes of each sleep stage; and in the latency to REM sleep. The lack of hypnotic activ- ity was evident when measured by self reports or by PSG measures. '̂'*-' MacFarlane and colleagues'*'* found a significant improvement in subjective assessments of sleep and daytime alertness in insomniacs given a much larger dose, 75mg, in a single, crossover placebo-controlled study. It is important to recognize that this dose is dramatically higher than the physi- ologic doses of melatonin (0.5-1 mg) and hence the safety of this dose requires study.
Melatonin appears to ameliorate secondary and age-related insomnia. Increased sleep efficiency was noted in both popula- tions after administration of melatonin.'*' Improved sleep effi- ciency occurred in an elderly population with doses of 0.1-3.0 mg which elevated plasma levels within normal range.'*''*'' Overall, the present data would suggest that melatonin is not an effective treatment for the management of primary insom- nia. However, it has clear phase shifting properties and hence it may have efficacy in elderly insomniacs with decreases in endogenous melatonin and insomnia associated with sleep circadian rhythm disorder.
Tryptophan
L-tryptophan is an essential amino acid that comes from food. Once absorbed, it can be converted to serotonin and mel- atonin. In the brain, serotonin is synthesized from tryptophan, which is the major metabolic route.'*^ Low levels of serotonin have been reported to be associated with depression, anxiety, and insomnia, and L-tryptophan supplements have been used to treat these disorders despite the absence of convincing data of its benefit.
The tryptophan-depletion model has been used to determine the association between tryptophan and sleep. Tryptophan depletion, following an ingestion of a trypto- phan-free ami.no acid drink, significantly increased stage 1 sleep and decreased stage 2 sleep. However, indices of sleep induction and sleep efficiency were not affected. Indices of REM density (the frequency of eye movements per unit of time during REM sleep) were significantly increased, whereas REM latency remained unaltered.'*"
L-tryptophan supplements appeared to be effective hypnotic agents in chronic insomniacs with sleep maintenance distur- bances that were characterized by 3-6 discrete awakenings during the night. Insomniacs self-reported 100% improvement following 1 g nightly administration for 1 week.'*' No consis- tent significant effects of L-tryptophan on sleep parameters determined by PSG were found in doses <] g. Significant decreases in sleep latencies were observed following 1-3 g of tryptophan but inconsistent findings were noted on total sleep time, SWS, and REM sleep.'*'
In a study by Schneider-Helmert and Spinweber,'" chronic insomniacs characterized by both sleep onset and sleep main- tenance problems showed therapeutic improvement occurring over time with repeated administration of low doses of L-tryp- tophan. The hypnotic effects appeared late in the treatment period or, as shown in some studies, even after discontinuation of treatment. L-tryptophan is also effective in reducing sleep onset time on the first night of administration in doses ranging from 1-15 g in young situational insomniacs.'"
The treatment of depression with the selective serotonin reuptake inhibitor fiuoxetine can exacerbate insomnia. The hypnotic effects of tryptophan in conjunction with an antidepressant were used to potentiate an improvement in insomnia. Tryptophan (2-4 g) and fiuoxetine (20 mg) administrated for 8 weeks significantly decreased depression scores and had a SWS protective effect. A significant decrease in SWS was noted in the fiuoxetine placebo group but not in the fiuoxetine-tryptophan group."
L-tryptophan administration has not been linked with impairments in visuomotor, cognitive, or memory perfor- mance.'" Some side effects of tryptophan can include drowsi- ness, tiredness/fatigue, nausea, loss of appetite, dizziness, head- ache, and dry mouth (Table 2).
ALCOHOL In 2001, approximately 30% of chronic insomniacs in the
general population reported using alcohol to induce sleep and GT^k of those reported that alcohol was effective.'̂ However, in PSG studies insomniacs who used alcohol had significandy impaired measures of sleep continuity and had more severe alcohol dependence and depression.'' Males and those never married or those separated or divorced/widowed are approxi- mately 1.5 times more likely to use alcohol as a sleep aid than females or those who are married.'"
Alcohol consumed at bedtime may decrease the time required to fall asleep and increase SWS. Because of alcohol's sedating effect, many people with insomnia consume alcohol to promote sleep. However, alcohol consumed within an hour of bedtime appears to disrupt the second half of the sleep period.'^" Alcohol affects the proportions ofthe various sleep stages with dose-dependent suppression of REM sleep. Higher
Primary Psychiatry 57 May 2008
S. Randall, T.A. Roehrs, T. Roth
doses of alcohol increased nocturnal awakenings and/or lighter stages of sleep (stage 1) during the second half of the night. The second-half disruption of sleep continuity is referred to as a "rebound effect," occurring as alcohol is metabolized or eliminated from the body.'*
Overall, the use of alcohol as well as the discontinuation of alcohol is associated with disturbances of sleep. This is most clearly seen in alcoholics who exhibit profoundly disturbed sleep during active drinking and after months of abstinence. Finally, the relation of alcohol consumption to improve sleep to the evolution of chronic alcoholism warrants study.
CONCLUSION Much of the data on the efficacy and safety of OTC sleep
aids is inconclusive and is associated with problems such as too few participants in the studies, little demographic and diag- nostic information regarding study participants, inconsistency in demographic and diagnostic information among studies to allow comparisons, lack of placebo-control groups, subjective reports with a lack of objective data, and short-term treatment with study medication which provides little indication about long-term usage.'̂
Treatment of insomnia with antihistamine-containing OTC sleep aids may help occasional mild insomnia. Prolonged use of some if not all antihistaminic drugs may result in tolerance and/or dependence and produce daytime sleepiness. The data on other non-prescription sleep aids is too limited or inconsis- tent in results to consider their use. While alcohol may have initial sedative effects, it is associated with rapid tolerance development and dose escalation (Table 2). PP
REFERENCES 1. Diagnostic anil Statisticai Manuai of Mental Disorders. 4th ed, text re». Washington, DC: American
Psychiatric Association; 2000. 2. Walsh JK. Clinicai and socioecononomic correlates ot insomnia. J Clin Psyciiiatry. 2004;65(suppi 8):13-19. 3. Ohayon MM. Epidemiology of insomnia: what we know and what we stiil need to learn. Steep Mei Rev.
2002:6(21:97-111. 4. Roth X Roehrs T. Insomnia: epidemioiogy, characteristics, and consequences, din Cornerstone. 2003:5(3):5-15. 5. Mofin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: prevaience, self-help treat-
ments, consultations, and determinants of help-seeking hehaviors. Sieep Med. 2006:7(2):123-13O. 6. Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S. The use ot non-prescription sleep products in the
elderly, int J Geriatr Psychiatiy. 1999;14(10):851-857. 7. Roehrs, T, Roth, T. Safety ot insomnia pharmacottierapy. In: Roth, T, ed. Sleep Medicine Clinics. Philadelphia,
PA: W.B. Saunders Company; 2006:399-407. 8. Roth I The relationship hetween psychiatric diseases and insomnia. IntJClin Pract Stippl. 2001;(l 16):3-8. 9. Morin AK, Jarvis CL, Lyncti AM. Therapeutic options tor sleep-maintenance and sieep-onset insomnia.
P h t h 2 m i l l { i m m 10. Johnson EO, Roehrs T Roth, T, Breslau N. Epidemioiogy of aicolioi and medication as aids to sleep in early
adulthood. Sieep. I998:21(2):178-186. 11. Morin CM, LeBlanc M, Daiey M, Gregoire JP, Mirette G. Epidemioiogy ot insomnia: prevaience, seif-heip treat-
ments, consultations, and determinants of help-seeking hehaviors. Sieep Med. 2006;7(2):123-130. 12. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am fam Piiysician. 2007:76(4):517-526. 13. Johnson JE. insomnia, aicohol, and over-the-counter drug use in old-old urban mmen. J Community Heaitti
Nurs. 1997:14(3):181-188. 14. Berider BG, Berning S, Dudden R, Milgrom H, Tran ZV. Sedation and performance impairment of diphenhydr-
amine and second generation antihistamine: a meta analysis. JAiiergyCiin immunoi. 2003;lll(4):770-776. 15. Kudo Y, Kurihara M. Ciinical evaluation ot diphenhydramine hydrochioride tor the treatment of insomnia in
psychiatric patients: a douhie blind study. J din Pharmacol. 1990:30:1041-1048.
16. Rickels K, Morris RJ, Newman H, Rosenteld H, Schiiier H, Weinstock R. Diphenhydramine in insomniac family practice patients: A double biind study. J Clin Pharmacol. 1983;23(5-6):234-242.
17. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Rotti I Tolerance to daytime sedative effects of HI antihistamines. yC//;)Psyi:topA3™a(;o/.2002;22(5):511-515.
18. Mumford CK, Siiverman K, Griffiths RR. Reinforcing, subjective and performance effects of lorazepam and diphenhydramine in humans. £xp Clin Psyctiopharmacol 1996;4(4): 421-430.
19. Rickel K, Ginsberg DO, Morris RJ, et al. Doxyiamine suocinate in insomniac tamiiy practice patients: a double- biind study. Curr TiierRes. 1984;35(4):532-540.
20. Leybishkis B, Fasseas P, Ryan KF. Doxylamine overdose as a potential cause of rtiabdomyolysis. Am J Med Sci. 2001;322(l):48-49.
21 Bliwise DL, Ansari FP. Insomnia associated with valerian and melatonin usage in tbe 2002 National Heaitb Interview Survey. Steep. 2007;30(7):881-884.
22. Taibi DM, Landis CA, Petiy H, Vitieilo MV. A systematic review ot valerian as a sieep aid: safe but not effective. Steep M e r f t e 2007: ll(3):209-230.
23. Ringdahi EN, Pereira SL, Deizeli JE. Treatment of primary insomnia. JAm Board Fam Pract. 2004;17(3):212-219. 24. Leatbwood PD, Gbautfard F, Heck E, Munoz-Box R. Aqueous extract of vaierian root (Vaieriana officinalis L.)
improves sieep quality in man. Pliarmacol Biocliem Behav. 1982:17(1):65-71. 25. Oominguez RA, Bravo-Valverde RL, Kapiowitz BR, Cott JM. Valerian as a hypnotic for Hispanic patients. Cultur
Divers Ethnic MinorPsychol. 2000;6(l):84-92. 26. Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Giasziou PP. Valerian does not appear to reduce symp-
toms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement TlierMed 2003;ll(4):215-222.
27. Jacobs BP, Bent S, Tice JA, Blackwell T, Gummings SR. An internet-based randomized, placebo-controiled trial of kava and vaierian for anxiety and insomnia. Medicine (Baitimore). 2005;84(4):197-207.
28. Balderer G, Borbely AA. Ettect ot valerian on human sleep. Psychopharmacology (Berl). 1985:87(4):406-409. 29. Leathwood PD, Chauffard F Aqueous extract of vaierian reduces iatency to tali asleep in man. Planta Med.
1985;51(2):144-148. 30. Schuiz H, Stolz C, Muller J. The effects of vaierian extract on sleep poiygraphy in poor sleepers: a piiot study.
f/ia™acops>tto(O'. 1994;27(4):147-151. 3 1 . Donatb F, Quispe S, Dietenbach K, Maurer A, Fietze I, Roots I. Ciinicai evaluation of the effects of valerian
extract on sieep structure and sieep quaiity. Ptiarmacopsychiatry. 2000;33(2):47-53. 32. Lindaiil 0, Lindwall L Double biind study ot a valerian preparation. Pharmacoi Biochem Behav. 1989;
32(41:1065-1066. 33. l.eathwood PD, Chautfard F, Heck E, Munoz-Box R. Aqueous extract ot vaierian root (Vaieriana otficinalis L.)
improves sieep quality in man. Pharmacol Biochem Behav 1982;17(1):65-71. 34. Meoii AL, Rosen G, Kristo D, et al. Orai nonprescription treatment for insomnia: an evaiuation of products
with iimited evidence. J Clin Sieep Med. 2005;l(2):173-187. 35. Pittler MH, Ernst E. Efficacy of kava extract tor treating anxiety: systematic review and meta-analysis. y c / / n
Psychopharmacol.2mQmUM-m. 36. Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum
Psyc/ioptormaco/. 2001;16(4):353-356. 37. Lehri S. Ciinicai efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders.
Results ot a multicenter, randomized, placebo-cpntrolied, double-blind ciinicai triai. J Affect Disord. 2004:78(2):101-110.
38. Chung, KF Melatonin use in sleep disorders HK Pract. 1997;19(12):669-672. 39. Eiiis CM, Lemmens G, Parkes JD. Meiatonin and insomnia, J Sleep Res. 1996:5(l):61-65. 40. Riemann D, Klein T, Rodenbeck A, et al. Nocturnal cortisoi and melatonin secretion in primary insomnia.
ftyc/«a//yffes. 2002;113(l-2):17-27, 4 1 . Almeida Montes LG, Ontiveros tJribe MP, Cortes Sotres J, Heinze Martin G. Treatment of primaiy insomnia witb
meiatonin: a double-biind, placebo-controiied, crossover study. J Psychiatry Neurosci. 2003;28(3):191-196. 42. James SP, Mendelson WB, Sack DA, Rosenthai, Wehr TA. The ettect of meiatonin on normal sieep.
Neuropsychopharmacoiogy 1987;l(l):41-44. 43. Buscemi N, Vanderriieer B, Pandya R, et al. Meiatonin tor treatmerit ot sleep disorders. Agency tor Healthcare
Research and Quality. Agency tor Healthcare Research and Quaiity. Avaiiabie at: www.ahrq.gov/ciinic/epc- sums/meiatsum.htm. Accessed March 19,2008.
44. MacFarlane JG, Cieghorn JM, Brown GM, Streiner DL. Tbe ettects ot exogenous meiatonin on tbe totai sleep time and daytime alertness ot chronic insomniacs: a preliminary study. Bid Psychiafiy. 1991;30(4):371-376.
45. Garfinkel D, Laudon M, Nof D, Zisapel N. improvement ot sieep quaiity in eideriy people by controlied-release meiatonin. Lancet 1995:346(8974):541-544.
46. Zhdanova iV, Wurtman RJ, Regan MM, Tayior JA, Shi JP, Leclair GU. Melatonin treatment for age-related insomnia. J din Endocrinoi Metab. 2001;86(10):4727-4730.
47. Mendelson WB. Circadian rhythms and sieep. In: Mendelson WB. Human Sleep Research and Clinical Care. Stony Brook, NY: Pienum MedicaiBook Company. 1987:295-313.
48. Lindsley JC, Hartmann EL, Mitchell W. Selectivity in response to L-tryptophan among insomniac subjects: a preliminary report. Steep. 1983:6(31:247-256.
49. Hajak G, Rodenbeck A, Rutber, E. Sleep-Inducing effects of l-tryptopban. In: Kocben W, Steinbart H, eds. L-trypto- phan Current Prospects in Medicine and Drug Safety. New York, NY: Waiter de Gruyter & Company: 1994:63-83.
50. Schneider-Helmert D, Spinweber CL Evaiuation ot L-tryptopban for treatment of insomnia: a review. Psychopharmacoiogy(Berl).\mm\).\-l.
51. Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro GM. Preliminary randomized doubie-blind placebo-controiled triai ot tiyptopban combined witb tluoxetine to treat major depressive disorder: antide- pressant and hypnotic effects. 7 ftyc/i/a(O'/Ve«rosa2000:25(4):337-346.
52. Ancoii-isaei, S., Rotb, T Characteristics of insomnia in the tinited States: resuits ot tbe 1991 Nationai Sleep Foundation Survey. I. Sleep 1999;22(suppi 21:347-353.
53. Brower KJ, Aldricb MS, Robinson EA, Zucker RA, Greden JF. insomnia, selt-medication, and relapse to aicobol- ism. Am 1 Psychiatry. 2001:158(31:399-404.
54. Roebrs T, Rotb I Sleep, sleepiness, and aicohol use. Alcohol Res Heaith. 2001;25(2):101-109. 55. Roehrs T, Papineau K, Rosenthai L, Roth T. Etbanoi as a hypnotic in insomniacs: selt administration and
ettects on sleep and mood, fteuropsychopharmacology. 1999;20(3):279-286. 56. American Academy of Sleep Medicine. Ciinicai Practice Review Committee. Do drugstores bave the cure tor
your insomnia? Taking a closer look at common treatments. Avaiiabie at: www.sieepeducation.com/Articie. aspx?id=2. Accessed March 19,2008.
Primary Psychiatry 58 May 2008